DAFNA Capital Management
Latest statistics and disclosures from DAFNA Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are STXS, XBI, RVMD, CYTK, ATRC, and represent 38.55% of DAFNA Capital Management's stock portfolio.
- Added to shares of these 10 stocks: SLNO, NKTR, RAPP, LRMR, AQST, MBX, CMPX, SPRY, INSP, ALKS.
- Started 7 new stock positions in CLDX, MBX, SPRY, OBIO, SLNO, RAPP, INSP.
- Reduced shares in these 10 stocks: BPMC (-$22M), MRUS (-$17M), MLYS (-$11M), ASND (-$7.9M), STOK (-$7.8M), URGN (-$6.4M), IDYA, KALV, Iteos Therapeutics, XBI.
- Sold out of its positions in ACET, BPMC, GOSS, Iteos Therapeutics, PVLA, PRCT, VYNE, IFRX.
- DAFNA Capital Management was a net seller of stock by $-67M.
- DAFNA Capital Management has $405M in assets under management (AUM), dropping by 11.74%.
- Central Index Key (CIK): 0001389933
Tip: Access up to 7 years of quarterly data
Positions held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 75 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Stereotaxis Com New (STXS) | 10.5 | $43M | 14M | 3.11 |
|
|
| Spdr S&p Biotech Etf Etf (XBI) | 9.9 | $40M | -3% | 402k | 100.20 |
|
| Revolution Medicines (RVMD) | 7.6 | $31M | -2% | 657k | 46.70 |
|
| Cytokinetics Com New (CYTK) | 5.4 | $22M | 395k | 54.96 |
|
|
| AtriCure (ATRC) | 5.2 | $21M | 592k | 35.25 |
|
|
| Merus N V (MRUS) | 5.1 | $21M | -44% | 221k | 94.15 |
|
| Ishares Nasdaq Biotech Indx Etf (IBB) | 3.7 | $15M | 103k | 144.37 |
|
|
| Ideaya Biosciences (IDYA) | 3.6 | $15M | -12% | 540k | 27.21 |
|
| Axogen (AXGN) | 3.3 | $13M | 742k | 17.84 |
|
|
| Xenon Pharmaceuticals (XENE) | 2.9 | $12M | 288k | 40.15 |
|
|
| Neurocrine Biosciences (NBIX) | 2.4 | $9.9M | 71k | 140.38 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 2.1 | $8.5M | 628k | 13.60 |
|
|
| Syndax Pharmaceuticals (SNDX) | 1.9 | $7.7M | -7% | 501k | 15.38 |
|
| Day One Biopharmaceuticals I (DAWN) | 1.7 | $7.0M | +13% | 999k | 7.05 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.6 | $6.6M | -54% | 33k | 198.81 |
|
| Ascendis Pharma A/s Note 2.250% 4/0 (Principal) | 1.3 | $5.4M | 4.0M | 1.36 |
|
|
| Kalvista Pharmaceuticals (KALV) | 1.3 | $5.1M | -27% | 423k | 12.18 |
|
| Bicara Therapeutics (BCAX) | 1.2 | $5.0M | 317k | 15.79 |
|
|
| Inogen (INGN) | 1.2 | $4.9M | 606k | 8.17 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 1.1 | $4.6M | 811k | 5.73 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 1.1 | $4.5M | 130k | 34.64 |
|
|
| Dex (DXCM) | 1.1 | $4.4M | 66k | 67.29 |
|
|
| Tandem Diabetes Care Com New (TNDM) | 1.1 | $4.3M | +20% | 355k | 12.14 |
|
| Kura Oncology (KURA) | 1.0 | $4.1M | 463k | 8.85 |
|
|
| Alkermes SHS (ALKS) | 1.0 | $4.0M | +29% | 135k | 30.00 |
|
| Stoke Therapeutics (STOK) | 1.0 | $4.0M | -66% | 170k | 23.50 |
|
| Soleno Therapeutics (SLNO) | 0.9 | $3.6M | NEW | 53k | 67.60 |
|
| Biohaven (BHVN) | 0.9 | $3.5M | 235k | 15.01 |
|
|
| Edgewise Therapeutics (EWTX) | 0.9 | $3.5M | -10% | 214k | 16.22 |
|
| Proqr Therapeutics N V Shs Euro (PRQR) | 0.8 | $3.3M | 1.6M | 2.13 |
|
|
| Larimar Therapeutics (LRMR) | 0.8 | $3.3M | +176% | 1.0M | 3.23 |
|
| Compass Therapeutics (CMPX) | 0.8 | $3.3M | +79% | 947k | 3.50 |
|
| Mineralys Therapeutics (MLYS) | 0.8 | $3.2M | -77% | 84k | 37.92 |
|
| Nektar Therapeutics Com New (NKTR) | 0.8 | $3.1M | +449% | 55k | 56.90 |
|
| Immunovant (IMVT) | 0.8 | $3.1M | 192k | 16.12 |
|
|
| Korro Bio (KRRO) | 0.7 | $2.9M | +5% | 61k | 47.89 |
|
| Aquestive Therapeutics (AQST) | 0.7 | $2.9M | +260% | 513k | 5.59 |
|
| Denali Therapeutics (DNLI) | 0.6 | $2.4M | 169k | 14.52 |
|
|
| Lexeo Therapeutics (LXEO) | 0.6 | $2.4M | -5% | 358k | 6.64 |
|
| Alector (ALEC) | 0.6 | $2.4M | -12% | 798k | 2.96 |
|
| Astria Therapeutics (ATXS) | 0.6 | $2.3M | 320k | 7.28 |
|
|
| Rapport Therapeutics (RAPP) | 0.6 | $2.2M | NEW | 75k | 29.70 |
|
| Tela Bio (TELA) | 0.5 | $2.1M | 1.4M | 1.49 |
|
|
| Insulet Corporation (PODD) | 0.5 | $2.1M | -30% | 6.9k | 308.73 |
|
| Mediwound Shs New (MDWD) | 0.5 | $2.0M | +76% | 114k | 18.02 |
|
| Accuray Incorporated (ARAY) | 0.5 | $2.0M | 1.2M | 1.67 |
|
|
| Immatics Nv SHS (IMTX) | 0.5 | $2.0M | -4% | 235k | 8.52 |
|
| Allogene Therapeutics (ALLO) | 0.4 | $1.7M | 1.4M | 1.24 |
|
|
| Viking Therapeutics (VKTX) | 0.4 | $1.7M | 65k | 26.28 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.4 | $1.7M | 218k | 7.59 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.4 | $1.7M | 59k | 28.00 |
|
|
| Mbx Biosciences (MBX) | 0.4 | $1.5M | NEW | 85k | 17.50 |
|
| Silverback Therapeutics (SPRY) | 0.3 | $1.4M | NEW | 141k | 10.05 |
|
| Align Technology (ALGN) | 0.3 | $1.4M | 11k | 125.22 |
|
|
| Keros Therapeutics (KROS) | 0.3 | $1.3M | -38% | 81k | 15.82 |
|
| Inspire Med Sys (INSP) | 0.3 | $1.3M | NEW | 17k | 74.20 |
|
| Oric Pharmaceuticals (ORIC) | 0.3 | $1.3M | -22% | 105k | 12.00 |
|
| Black Diamond Therapeutics (BDTX) | 0.3 | $1.2M | -34% | 307k | 3.79 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.2 | $902k | NEW | 364k | 2.48 |
|
| Brainsway Sponsored Ads (BWAY) | 0.2 | $859k | -55% | 57k | 15.07 |
|
| Century Therapeutics (IPSC) | 0.2 | $849k | 1.7M | 0.50 |
|
|
| Erasca (ERAS) | 0.2 | $763k | 350k | 2.18 |
|
|
| Polypid (PYPD) | 0.2 | $693k | 208k | 3.33 |
|
|
| Biontech Se Sponsored Ads (BNTX) | 0.2 | $690k | 7.0k | 98.62 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.2 | $634k | NEW | 25k | 25.87 |
|
| Foghorn Therapeutics (FHTX) | 0.2 | $620k | -57% | 127k | 4.89 |
|
| Urogen Pharma (URGN) | 0.1 | $549k | -92% | 28k | 19.95 |
|
| Neurogene (NGNE) | 0.1 | $526k | -40% | 30k | 17.33 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.1 | $499k | 65k | 7.74 |
|
|
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $488k | 122k | 4.00 |
|
|
| Compugen Ord (CGEN) | 0.1 | $400k | 272k | 1.47 |
|
|
| Sutro Biopharma (STRO) | 0.1 | $380k | 437k | 0.87 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $292k | -57% | 179k | 1.63 |
|
| Biomx Com New (PHGE) | 0.1 | $211k | 401k | 0.53 |
|
|
| Aprea Therapeutics Com New (APRE) | 0.0 | $202k | 137k | 1.48 |
|
Past Filings by DAFNA Capital Management
SEC 13F filings are viewable for DAFNA Capital Management going back to 2010
- DAFNA Capital Management 2025 Q3 filed Nov. 14, 2025
- DAFNA Capital Management 2025 Q2 filed Aug. 14, 2025
- DAFNA Capital Management 2025 Q1 filed May 15, 2025
- DAFNA Capital Management 2024 Q4 filed Feb. 14, 2025
- DAFNA Capital Management 2024 Q3 filed Nov. 14, 2024
- DAFNA Capital Management 2024 Q2 filed Aug. 14, 2024
- DAFNA Capital Management 2024 Q1 filed May 15, 2024
- DAFNA Capital Management 2023 Q4 filed Feb. 14, 2024
- DAFNA Capital Management 2023 Q3 filed Nov. 14, 2023
- DAFNA Capital Management 2023 Q2 filed Aug. 14, 2023
- DAFNA Capital Management 2023 Q1 filed May 15, 2023
- DAFNA Capital Management 2022 Q4 filed Feb. 14, 2023
- DAFNA Capital Management 2022 Q3 filed Nov. 14, 2022
- DAFNA Capital Management 2022 Q2 filed Aug. 15, 2022
- DAFNA Capital Management 2022 Q1 filed May 16, 2022
- DAFNA Capital Management 2021 Q4 filed Feb. 14, 2022